NAD-ME antibody
-
- Target See all NAD-ME Antibodies
- NAD-ME (NAD Dependent Malate Dehydrogenase (NAD-ME))
-
Reactivity
- Human, Mouse, Rat
-
Host
- Rabbit
-
Clonality
- Polyclonal
-
Conjugate
- This NAD-ME antibody is un-conjugated
-
Application
- Western Blotting (WB)
- Purification
- Affinity purified
- Immunogen
- ME2 antibody was raised using a synthetic peptide corresponding to a region with amino acids MAFTLQERQMLGLQGLLPPKIETQDIQALRFHRNLKKMTSPLEKYIYIMG
- Top Product
- Discover our top product NAD-ME Primary Antibody
-
-
- Application Notes
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. - Comment
-
ME2 Blocking Peptide, catalog no. 33R-5654, is also available for use as a blocking control in assays to test for specificity of this ME2 antibody
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of ME2 antibody in PBS
- Concentration
- Lot specific
- Buffer
- PBS
- Handling Advice
- Avoid repeated freeze/thaw cycles.
- Storage
- 4 °C/-20 °C
- Storage Comment
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
- Target
- NAD-ME (NAD Dependent Malate Dehydrogenase (NAD-ME))
- Alternative Name
- ME2 (NAD-ME Products)
- Synonyms
- ODS1 antibody, AW120568 antibody, D030040L20Rik antibody, NAD-ME antibody, zgc:100941 antibody, malic enzyme 2 antibody, malic enzyme 2, NAD(+)-dependent, mitochondrial antibody, malic enzyme 2, NAD(+)-dependent, mitochondrial S homeolog antibody, ME2 antibody, Me2 antibody, me2.S antibody, me2 antibody
- Background
- ME2 is a mitochondrial NAD-dependent malic enzyme, a homotetrameric protein, that catalyzes the oxidative decarboxylation of malate to pyruvate. It had previously been weakly linked to a syndrome known as Friedreich ataxia that has since been shown to be the result of mutation in a completely different gene.
- Molecular Weight
- 65 kDa (MW of target protein)
- Pathways
- Production of Molecular Mediator of Immune Response
-